Months 0-6: Initial Weight Loss Phase The first six months of semaglutide treatment typically produce the most dramatic weight loss, with patients often losing 10-15% of their initial body weight
Nausea: 3,590 Severe Vomiting: 2,031 Pancreatitis: 607 Abdominal Distension: 555 Abdominal Pain: 548 Abdominal/Stomach Pain: 512 Gastroesophageal Reflux Disease: 274 Gastrointestinal Disorder: 240 Acute Kidney Injury: 196 Cholelithiasis: 119 Renal Failure: 92 Impaired Gastric Emptying: 82 Gastric Disorder: 65 Gastritis: 60 Gallbladder Disorder: 48 Gastroenteritis: 31 Ozempic Warning Label Failures Despite thousands of adverse reactions being reported by individuals taking Ozempic within the first several years of being on the market, the manufacturer failed to issue a timely warning
Gooley JJ, Chamberlain K, Smith KA, Khalsa SB, Rajaratnam SM, Van Reen E, et al
Semaglutide is a GLP-1 receptor agonist that mimics the body's natural hormones to help regulate appetite, improve satiety, and slow digestion
This location was specifically chosen in clinical trials to provide reliable, predictable absorption rates
It's not Now
